Pain and continued opioid use in individuals receiving buprenorphine-naloxone for opioid detoxification: secondary analyses from the Clinical Trials Network.
Potter
Jennifer Sharpe
JS
Division of Alcohol and Drug Abuse, Department of Psychiatry, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA. potterjs@uthscsa.edu
Chakrabarti
Amit
A
Domier
Catherine P
CP
Hillhouse
Maureen P
MP
Weiss
Roger D
RD
Ling
Walter
W
D000328:Adult; D000701:Analgesics, Opioid / Q000009:adverse effects / Q000627:therapeutic use*; D002047:Buprenorphine / Q000627:therapeutic use*; D000069479:Buprenorphine, Naloxone Drug Combination; D004338:Drug Combinations; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009270:Naloxone / Q000627:therapeutic use*; D009292:Narcotic Antagonists / Q000627:therapeutic use; D009293:Opioid-Related Disorders / Q000150:complications / Q000534:rehabilitation*; D010146:Pain / Q000150:complications / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic; D012720:Severity of Illness Index; D013375:Substance Withdrawal Syndrome / Q000534:rehabilitation
D000701:Analgesics, Opioid; D000069479:Buprenorphine, Naloxone Drug Combination; D004338:Drug Combinations; D009292:Narcotic Antagonists; D009270:Naloxone; D002047:Buprenorphine